4D Molecular Therapeutics (4DMT) is a clinical-stage biotherapeutics company focused on harnessing the power of directed evolution to develop targeted genetic medicines. Utilizing their innovative platform, Therapeutic Vector Evolution (TVE), 4DMT aims to unlock the full potential of gene therapy by creating evolved vectors from a vast library of synthetic AAV capsid-derived sequences. The company is distinguished by its fully integrated clinical-phase operations, internal manufacturing capabilities, and a robust pipeline that includes five candidate products in the clinic and two pre-clinical programs. With a commitment to addressing a broad range of large market diseases, 4DMT is positioned to advance the field of genetic medicine beyond the traditional focus on rare diseases.